Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact

Core Insights - Abbott Laboratories (NYSE:ABT) is recognized as one of the 12 Most Profitable Dividend Stocks to consider for investment in 2026 [1] - Evercore ISI has reduced its price target for Abbott from $144 to $138 while maintaining an Outperform rating, indicating confidence in the company's long-term growth despite recent challenges [2] - Abbott's recent quarterly performance missed Wall Street's revenue expectations, leading to a 7% decline in share price, primarily due to underperformance in the nutrition and diagnostics segments [2][4] Financial Performance - The nutrition segment experienced an 8.9% decline in sales year-over-year, totaling $1.94 billion, while diagnostics revenue fell by 2.5% to $2.46 billion, raising concerns about the company's near-term momentum [4] - Rising production costs have compelled Abbott to increase prices, which has negatively impacted consumer demand as price sensitivity grows [4] Business Overview - Abbott Laboratories operates as a global healthcare company with a diverse portfolio that includes diagnostics, medical devices, nutrition, and branded generic medicines [5]